There are currently two inhibitors, namely, pralsetinib (BLU-667 or X581238) and selpercatinib (LOXO 292), that are FDA and EMA approved based on ARROW trials and the LIBRETTO-001, for only RET-altered non-small cell lung cancer (NSCLC) and thyroid cancer (5) and locally advanced or metastatic RET fusion-positive solid tumors, respectively. This evidence concerns the gene RET and thyroid gland carcinoma.